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X-linked sideroblastic anemia due to ALAS2 intron 1
enhancer element GATA-binding site mutations
Dean R. Campagna,1† Charlotte I. de Bie,2 Klaus Schmitz-Abe,3,4 Marion Sweeney,5 Anoop K. Sendamarai,1
Paul J. Schmidt,1 Matthew M. Heeney,6 Helger G. Yntema,7 Caroline Kannengiesser,8 Bernard Grandchamp,8
Charlotte M. Niemeyer,9 Nine V.A.M. Knoers,2 Sonia Swart,10 Gordon Marron,11 Richard van Wijk,12
Reinier A. Raymakers,13 Alison May,5 Kyriacos Markianos,3,4 Sylvia S. Bottomley,14 Dorine W. Swinkels,15
and Mark D. Fleming1*
X-linked sideroblastic anemia (XLSA) is the most common form of congenital sideroblastic anemia. In
affected males, it is uniformly associated with partial loss-of-function missense mutations in the erythroid-
specific heme biosynthesis protein 5-aminolevulinate synthase 2 (ALAS2). Here, we report five families with
XLSA owing to mutations in a GATA transcription factor binding site located in a transcriptional enhancer
element in intron 1 of the ALAS2 gene. As such, this study defines a new class of mutations that should be
evaluated in patients undergoing genetic testing for a suspected diagnosis of XLSA.
Am. J. Hematol. 89:315–319, 2014. VC 2013 Wiley Periodicals, Inc.
 Introduction
The sideroblastic anemias are a heterogeneous group of inherited and acquired hematological disorders characterized by the presence of ring
sideroblasts—erythroblasts containing pathological mitochondrial iron deposits—in the bone marrow. The inherited or congenital sideroblastic
anemias (CSAs) are uncommon diseases, typically characterized by germline genetic mutations leading to defects in mitochondrial heme synthesis,
iron–sulfur cluster metabolism, or protein synthesis (reviewed in Ref. 1). Currently, nearly 60% of CSAs can be attributed to a mutation in a spe-
cific nuclear-encoded gene or mitochondrial DNA deletion [2]. Two-thirds or more of all genetically explained cases are due to mutations in 5-
aminolevulate synthase 2 (ALAS2), the erythroid-specific isoform of the first, and rate-limiting, enzyme in heme biosynthesis, located on the X
chromosome. Mutations in ALAS2 lead to a hypochromic, microcytic CSA that occurs most commonly in males, and is commonly referred to as
X-linked sideroblastic anemia (XLSA). All experimentally validated ALAS2 mutations described thus far in male probands are missense mutations,
most often in domains important for catalysis or pyridoxal phosphate (vitamin B6) cofactor binding. In many cases, the anemia is responsive to
high-dose dietary supplementation with pyridoxine, which stabilizes or otherwise promotes the activity of the mutant protein [3]. Females develop
anemia in the setting of acquired unfavorably skewed X chromosome inactivation, and, unlike males, may have predicted null mutations that pre-
maturely truncate the protein [4]. Clinically unaffected heterozygous carrier females may have a frankly bimodal red cell size distribution, but,
more often, have subtle laboratory and morphological red blood cell (RBC) abnormalities such as an increased RBC distribution width (RDW)
and occasional hypochromic microcytic RBCs or siderocytes on the peripheral blood smear. In some cases, they may have no morphological
abnormalities whatsoever.
Additional Supporting Information may be found in the online version of this article.
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 Methods
Probands in each family were ascertained based on the evaluation of clinical
and pathological features, including a bone marrow aspiration showing ringed side-
roblasts. Patient and family member samples for investigational studies were
obtained with informed consent. Peripheral blood genomic DNA was used for all
analyses. Except as noted, all genomic coordinates refer to the human genome
sequence alignment release 19 (GRCh37/hg19) and were accessed using the UCSC
Genome Browser (http://genome.ucsc.edu/) [5]. Genotyping was performed with
Affymetrix 6.0 SNP chips in families A, F, and P using standard protocols. These
three families are a subset of 300 typed individuals in a collaborative CSA data-
base (M.M.H., D.R.C., A.M., C.K., B.G., C.N., D.W.S., S.S.B., and M.D.F., unpub-
lished) maintained at Boston Children’s Hospital, and analyzed using a custom
build, rule-based pipeline that integrates copy number variation (CNV) and family
linkage with population level homozygosity and allele sharing. A detailed descrip-
tion of the software will be published elsewhere (Schmitz-Abe et al., unpublished).
We delineated the minimal 17.3-Mb interval on chromosome X shared between the
three American families (A, F, and P) using this pipeline and a 98% allelic identity
threshold for pairs of individuals. In addition to CNV analysis based on Affymetrix
6.0 typing, we tested a subset of samples for small deletions using a custom Nimbl-
gen 720k array covering chrX: 50,040,914–79,999,613 (hg18), with a median probe
density of 50 bp. Data analysis was performed using Nimblescan 2.6. Bidirectional
Sanger sequencing of patient genomic DNA was performed on samples amplified
by polymerase chain reaction (PCR) using the primers listed in Supporting Infor-
mation Table I. For quantitative real-time (RT)-PCR, total erythrocyte RNA was
prepared from heparinized blood [6]. RNA was treated with DNase I (Roche) to
remove contaminating genomic DNA. cDNA was synthesized using the iScriptTM
cDNA Synthesis Kit (Bio-Rad) according to the manufacturer’s protocol. RT-PCR
quantification of ALAS2 [7] and a-globin-stabilizing protein (AHSP) [8] mRNA
transcript levels was performed as described previously [9]. X-inactivation was per-
formed using the HUMARA assay [10]. In Table I, in carrier females, the relative
“activation” of the mutant allele compared to the wild-type allele is expressed as a
fraction. A ratio of 1 indicates that there is equal activation of both alleles, whereas
ratios of >1 indicate that the X chromosome carrying the mutant ALAS2 is more
active than the wild-type X chromosome (and vice versa).
 Results and Discussion
We ascertained five families of Northern European descent—three
American, one Dutch, and one British—in which affected male pro-
bands had hypochromic, microcytic CSA that was in several cases
minimally or partially responsive to pyridoxine supplementation
(Fig. 1A and Table I). In three pedigrees (Fig. 1A, Families A, F, and
N), there was strong evidence of X linkage by the presence of multi-
ple affected males distantly related through the maternal lineage and/
or multiple generations of females, but not males, with hematological
features consistent with XLSA carrier status. In one family, a female
sibling (N-IV-3) of the three affected brothers was found to have iron
overload and clinically significant hematologic abnormalities upon
family screening. In this individual, the HUMARA X-inactivation
assay was not informative; however, the degree of hematological
abnormality, particularly the RDW, tended to be greater in those
females in this and all other families with X-inactivation skewed
toward the mutated X chromosome. Male probands did not have
mutations in the exons and intron–exon boundaries of ALAS2 or
GLRX5 (all families) or SLC25A38 (families A, F, P, and N) [11,12].
In two families (Fig. 1A, Families A and F), deletions greater than
250 bp were excluded using Affymetrix 6.0 SNP genotypes and a
custom genomic tiling array spanning the entire ALAS2 locus to the
nearest flanking genes. Comparison of the SNP haplotypes on the X
chromosome in the three American families (Families A, F, and P),
however, demonstrated partially overlapping blocks of allelic identity
in the vicinity of the ALAS2 locus: the minimally shared region
spanned a distance of 17.3 Mb (hg 18, Chr. X: 44,922,272–
72,277,688), including the entire ALAS2 locus, and segregated with
the phenotype and presumptive female carrier state in the two fami-
lies (Families A and F) in which multiple relatives were available.
Portions of this haplotype were not present in 134 other males with
CSA and their male family members, suggesting that this was not an
unusually common haplotype and that these three families were
ancestrally related. Although none of these individuals had cerebellar
ataxia or other syndromic features, mutations in the mitochondrial
ATP-binding cassette transporter ABCB7, responsible for XLSA with
ataxia (XLSA/A) [13], and located 2 Mb distal to the minimally con-
served haplotype, were also excluded by sequencing PCR-amplified
exons. Similarly, Family N had no ABCB7 mutations detected by
sequencing.
These data strongly suggested that the phenotype could be attributed
to a mutation closely linked to ALAS2, if not a regulatory or other non-
coding or splicing mutation affecting ALAS2 expression itself. To this
end, in probands from all five families, we examined previously described
and putative regulatory elements that promote erythroid ALAS2 expres-
sion, including: 2.6 kilobases (kb) of sequence immediately upstream of
the transcriptional start site (TSS), containing the putative promoter [14],
as well as two regions (chrX: 55,083,769–55,085,031 and chrX:
55,142,627–55,148,312) located 25 and 85 kb upstream of the TSS
with extensive histone H3 lysine 27 acetylation (H3K27Ac) in K562
human erythroleukemia cells [15]. We also sequenced a previously
defined enhancer element in intron 8 [16] in these five individuals, as
well as 68 other genetically undefined CSA probands. In each case, analy-
sis revealed nothing other than common variants or rare, unique variants
that did not cluster or occur within evolutionarily conserved sequences.
The complete sequence of ALAS2 intron 1 in families A and F, however,
which also has extensive H3K27Ac modification in K562 cells [15],
revealed a A>G transition at chromosomal position X: 55054635
[ChrX(GRCh37/hg19):g.55054635A>G, NM_000032.4:c.215–2187T>C]
as shown in Fig. 1B. Analysis of this locus in the remaining three index
families demonstrated, novel variants in adjacent nucleotides in Families
C [ChrX(GRCh37/hg19):g.55054636 T>C; NM_000032.4:c.215–
2188A>G) and N (ChrX(GRCh37/hg19):g.55054634G>C; NM_000032.
4:c.215–2186C>G), and, as expected, the same g.55054635A>G variant
in Family P. These variants all fall in the core GATA sequence element
of a phylogenetically conserved GATA family transcription factor binding
site (consensus sequence: [A/G]GATA[A/G]). Variants in this sequence
were not present in 95 other unexplained CSA probands (including the
68 sequenced for intron 8 variants) having a wide variety of syndromic
and nonsyndromic features [2] or in 69 whole genomes (K.S.-A. and K.
M., unpublished).
The potential importance of such GATA-binding sites in hemato-
logical diseases is illustrated by the existence of mutations in GATA-
binding sites in occasional patients with pyruvate kinase deficiency
[17], as well as mutations in GATA1 and GATA2 themselves in fami-
lial erythroid, megakaryocytic, and hematopoietic syndromes [18–20].
Previous studies by Wang et al. demonstrated that this particular
ALAS2 intron 1 sequence element displays strong enhancer activity
both in transiently transfected K562 cells as well as a stably targeted
K562 reporter assay cell line induced to differentiate along the ery-
throid lineage [21]. When mutated, this sequence is unable to pro-
mote transcription of the reporter, confirming its functional
significance. Furthermore, as assessed by chromatin immunoprecipita-
tion, binding to this site in GATA1-ER cells is strongly induced by
treatment with estradiol, which regulates translocation of GATA1
protein linked to the estrogen receptor regulatory domain in this cell
line, promoting terminal differentiation and marked upregulation of
Alas2 gene expression. More recent, systematic chromatin immuno-
precipitation experiments indicate that this element and adjacent
sequences, are occupied by GATA1 and TAL1 proteins [15], whose
colocalization is strongly associated with active erythroid promoter
and enhancer elements [22]. Finally, in vitro selection of GATA-
binding sites demonstrates a near absolute requirement for the first
three nucleotides—G, A, and T—in the GATA-binding site core, each
of which is mutated in at least one of the families we studied, for
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binding to GATA1, GATA2, and GATA3 proteins [23,24]. Similarly,
site-directed mutagenesis of other naturally occurring GATA-binding
sites indicates that these three nucleotides are critical for complex for-
mation, whereas the fourth nucleotide is less important. In fact, Plumb
et al. compared the relative affinities of consensus GATA-binding ele-
ments to precisely the same nucleotide variants present in Families A,
F, and P and C and found that these mutant oligonucleotides were
<4,000- and <3,000-fold, respectively, less-efficient at competing the
consensus probe in electrophoretic mobility shift assays (EMSAs) using
mouse erythroleukemia cell nuclear extracts [25].
To determine if the mutations affected ALAS2 mRNA abundance,
we performed quantitative PCR using RNA isolated from patient and
control peripheral blood RBC samples. As shown in Fig. 2, ALAS2
mRNA levels normalized to the erythroid-specific AHSP showed that
there was substantially less ALAS2 mRNA in patient P-II-2 than in
control individuals, patients with CSA owing to mutations in
SLC25A38, and all but one XLSA patient with a missense mutation in
ALAS2. Although limited to this single patient, the findings support
the interpretation that mutations in this GATA element can result in
decreased ALAS2 mRNA expression.
Our findings strongly indicate that the conserved GATA element
is an erythroid enhancer and that the patient-associated alleles are
functionally significant mutations owing to the interruption of
GATA1 binding. It is not possible to make definitive genotype–phe-
notype correlations, as even within a family (e.g., Family N) there is a
great deal of phenotypic variability, suggesting a variety of modifying
factors, both genetic and otherwise.
During the course of this study, we became aware of a similar
study by Kaneko et al. [26], who confirmed the presence of a func-
tional GATA-binding site-dependent erythroid enhancer element in
intron 1 of ALAS2, using an approach entirely independent of that
published previously [21]. Therein, they also describe mutations in
the enhancer in three Japanese male probands with hypochromic,
microcytic CSA; one of these was from an extended pedigree, demon-
strating apparent X-linkage. One mutation, 55054635A>G, present in
two of the probands is identical to that found in Families A, F, and P
and the other is a 37-bp deletion that encompasses the entire
GATA-binding site. They confirm that the former mutation, in con-
cordance with the findings of Wang et al. [21], as well as the novel
deletion, abrogates DNA binding in EMSAs and that both mutations
substantially diminish erythroid-specific enhancer activity. Finally,
similar to our observation, they show a decrease in ALAS2 expression
in primary cells from one patient.
 Conclusions
Taken together, these genetic and functional data strongly support
the conclusion that mutations in an enhancer element in ALAS2
intron 1 that contains a GATA-binding site result in a clinical pheno-
type similar to patients with XLSA owing to mutations in the ALAS2
coding sequence itself. In our own survey of >125 probands with
CSA (Ref. 2 and data not shown), ALAS2 intron 1 enhancer element
mutations constitute 3% of all probands and 5% of cases of
XLSA. For this reason, we suggest that ALAS2 intron 1 GATA-
binding site variants can be excluded in males with hypochromic,
microcytic, nonsyndromic sideroblastic anemias lacking coding muta-
tions in ALAS2 or biallelic coding or splicing variants in SLC25A38,
particularly those with clinical or laboratory evidence of X-linkage or
a minimal, but discernable, response to pyridoxine therapy.
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